Welcome to our dedicated page for Incannex Healthcare SEC filings (Ticker: ixhl), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial updates, patent disclosures, and convertible-note financing details make Incannex Healthcare’s SEC documents uniquely dense. If you have ever searched for “Incannex Healthcare SEC filings explained simply,” you know how hard it is to decode cannabinoid and psychedelic trial data buried across dozens of forms.
Stock Titan solves this by pairing real-time EDGAR feeds with AI that translates technical jargon into clear language. Whether you need the “Incannex Healthcare quarterly earnings report 10-Q filing” (or its foreign filer equivalent), “Incannex Healthcare insider trading Form 4 transactions,” or an “Incannex Healthcare 8-K material events explained,” our platform surfaces the line items that move markets. Key features include:
- Instant alerts for “Incannex Healthcare Form 4 insider transactions real-time” and “Incannex Healthcare executive stock transactions Form 4.”
- AI-powered summaries of trial milestones inside 6-K/8-K releases and the “Incannex Healthcare earnings report filing analysis.”
- Side-by-side comparisons that make the “Incannex Healthcare annual report 10-K simplified” (and 20-F equivalents) readable in minutes.
- Easy access to the “Incannex Healthcare proxy statement executive compensation” so you can see how leadership is rewarded as new therapies progress.
Use our expert analysis to track segment spending on obstructive sleep apnea trials, monitor licensing revenue, and benchmark R&D burn—without parsing hundreds of pages manually. Understanding Incannex Healthcare SEC documents with AI lets you spot insider confidence before material announcements, compare quarter-over-quarter cash usage, and act on data that matters. Complex biotech filings, clarified.
Incannex Healthcare Inc. (IXHL) reported its September 30, 2025 quarter with higher liquidity and a wider loss. The company recorded a net loss of
Liquidity strengthened materially during the quarter. Cash and cash equivalents increased to
Operations and programs continued. The Phase 2/3 RePOSA trial for IHL-42X remained the primary R&D spend driver. Revenue from customers was zero for the quarter. The company maintained its prior disclosure of a material weakness in internal control over financial reporting and outlined ongoing remediation steps.
Incannex Healthcare (IXHL) director Troy Valentine reported acquiring 11,302,608 shares of common stock at $0 on November 14, 2025, as a restricted stock grant under the company’s 2023 Equity Incentive Plan. Following the grant, he beneficially owned 12,001,858 shares directly.
The restricted shares vest in four tranches of 2,825,652 each on December 10, 2025; June 30, 2026; June 30, 2026; and June 30, 2027. He also reported indirect holdings, including 242,862 shares via Alignment Capital Pty Ltd.
Incannex Healthcare (IXHL) director Robert Clark reported acquiring 1,686,956 shares of common stock on 11/14/2025 at $0, granted as restricted stock under the 2023 Equity Incentive Plan. Following the grant, he beneficially owns 1,786,956 shares, held directly.
The award vests in four tranches: 421,739 on December 10, 2025; 421,739 on June 30, 2026; 421,739 on June 30, 2026; and 421,739 on June 30, 2027.
Incannex Healthcare (IXHL) reported a director’s Form 4 showing an acquisition of 1,686,956 shares of restricted common stock at $0 on November 14, 2025 under the company’s 2023 Equity Incentive Plan. The award vests in four tranches: 421,739 on December 10, 2025, 421,739 on June 30, 2026, another 421,739 on June 30, 2026, and 421,739 on June 30, 2027. Following the grant, the reporting person beneficially owns 1,957,803 shares, held directly.
Incannex Healthcare (IXHL) reported an insider equity grant. The company’s CFO, Treasurer and Secretary received 869,565 shares of common stock at $0 on 11/14/2025, reported as an acquisition. Following the grant, beneficial ownership stands at 921,358 shares, held directly. The award is restricted stock under the 2023 Equity Incentive Plan, vesting in three equal tranches of 289,855 shares on 12/10/2025, 06/30/2026, and 06/30/2027.
Incannex Healthcare (IXHL) reported an insider equity grant on Form 4. CEO/President and Director Joel Latham acquired 22,608,692 shares of common stock on November 14, 2025 at a price of $0 (transaction code A). Following the grant, his beneficial ownership stands at 24,186,177 shares, held directly.
The filing states these are restricted shares granted under the company’s 2023 Equity Incentive Plan, with vesting in four equal tranches of 5,652,173 shares each: December 10, 2025, June 30, 2026 (two tranches), and June 30, 2027. This outlines the schedule by which the award becomes fully vested over time.
Incannex Healthcare (IXHL) director George Anastassov reported an acquisition of 1,686,956 shares of common stock on 11/14/2025, at a reported price of $0, reflecting a restricted stock grant under the 2023 Equity Incentive Plan. Following the transaction, he beneficially owns 2,456,677 shares, held directly.
The grant includes four equal tranches of 421,739 shares scheduled to vest on Dec 10, 2025, Jun 30, 2026 (two tranches), and Jun 30, 2027.
Incannex Healthcare Inc. (IXHL) filed a Form S-8 to register an additional 69,541,101 shares of common stock issuable under its 2023 Equity Incentive Plan, as amended on May 27, 2025, pursuant to the plan’s “evergreen” provision. The filing incorporates prior S-8 registrations for the same plan by reference under General Instruction E.
This expands the share pool available for employee and director equity awards and maintains continuity with the company’s existing plan framework.
FAQ
What is the current stock price of Incannex Healthcare (ixhl)?
What is the market cap of Incannex Healthcare (ixhl)?
